Serum insulin and leptin levels in valproate-associated obesity.
about
Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care.Metabolic syndrome and migraine.Polycystic ovary syndrome in women using valproate: a review.Cardiovascular morbidity and mortality in bipolar disorder.Leptin consumption in the inflamed joints of patients with rheumatoid arthritisObesity, polycystic ovarian syndrome and thyroid dysfunction in women with epilepsy.Antiepileptic drugs and the risk of ischaemic stroke and myocardial infarction: a population-based cohort studySystematic Review and Meta-analysis of Pharmacological Interventions for Weight Gain from Antipsychotics and Mood Stabilizers.Endocrine and metabolic changes in epileptic patients receiving valproic acid.Optimizing epilepsy management in teenagers.Elevated prevalence of obesity, metabolic syndrome, and cardiovascular risk factors in bipolar disorderEffect of valproic acid on body weight, food intake, physical activity and hormones: results of a randomized controlled trial.Manic/hypomanic symptom burden and cardiovascular mortality in bipolar disorder.Epilepsy, sex hormones and antiepileptic drugs in female patients.Weight gain following treatment with valproic acid: pathogenetic mechanisms and clinical implications.Histone deacetylase (HDAC) inhibition as a novel treatment for diabetes mellitus.Weight change, genetics and antiepileptic drugs.Antiepileptic drugs influences on body weight in people with epilepsy.Valproic acid and nonalcoholic fatty liver disease: A possible association?Modification in body weight associated with antiepileptic drugs.Serum insulin and leptin levels and valproate-associated obesity.Body mass index and serum lipid changes during treatment with valproic acid in children with epilepsy.Insulin resistance in patients on valproic acid: relation to adiponectin.Growth and lipid metabolism in girls and young women with epilepsy during pubertal maturation.Weight change in monozygotic twins treated with valproate.Fatty liver in adults receiving antiepileptic medications: relationship to the metabolic risks.The role of ghrelin in weight gain and growth in epileptic children using valproate.Serum insulin, leptin, and neuropeptide y levels in epileptic children treated with valproate.Weight and fat distribution in patients taking valproate: a valproate-discordant gender-matched twin and sibling pair study.Evaluation of adiponectin and leptin levels and oxidative stress in bipolar disorder patients with metabolic syndrome treated by valproic acid.Comparative effectiveness of switching antipsychotic drug treatment to aripiprazole or ziprasidone for improving metabolic profile and atherogenic dyslipidemia: a 12-month, prospective, open-label study.Plasma leptin, neuropeptide Y, ghrelin, and adiponectin levels and carotid artery intima media thickness in epileptic children treated with valproate.Characterization of insulin secretion in Valproate-treated patients with epilepsy.
P2860
Q34623350-16558171-7E21-4251-B964-5912FF4388D7Q34645695-3BA65C89-8FE4-4731-95E1-0BBC5209D322Q34881401-D4A95765-EE36-4C50-B99C-77A703C30A09Q35313130-CF86D20C-12B3-43F6-B6ED-FE7FB820D64BQ35552048-61F224FD-50C1-4B1A-A403-D083507402C9Q35937900-C1003394-05B4-4B43-90B4-B9B656A5D648Q35960111-56C18971-7109-4ABA-9026-EE60B047F9A0Q36034676-A18767E5-B744-41F9-8453-7B5A510D88E3Q36142002-EE8704F1-0F17-445F-A240-8E68F0262CFBQ36561919-7EC326BB-79A9-46C6-B3F0-AD09228B87F7Q37218782-EECFE8E6-FB11-48A6-A345-B63594C50C2DQ37366007-01BE484B-560B-489E-B54F-DC42ED09C331Q37426682-7411EDD9-6F4D-491D-A541-5FCC3F6660ADQ37642006-E5887F79-C144-45CA-AB8F-D3E968FF829DQ37794213-DB48878F-A43E-4881-BE1E-2F9F2B3DAF63Q37832964-36501CC0-2E3C-4ABD-9D5E-B6093989186CQ38168942-87072794-65DD-4C7C-8473-9CB1A0F94684Q38285318-3DE23015-542C-4183-856F-E3DAD4615301Q38505408-777B22BA-198A-4A74-BEDF-605C4FFF9B96Q43065224-DF5C44B8-58C9-46DB-9249-C4036891CF78Q44667902-32058966-3217-40D1-B390-5AF0CA452BE1Q46208501-BC35C4C8-D391-4012-9DE1-F99E21609B9EQ46601959-28A9949A-FA58-4292-9C13-D7F149B95A56Q46606260-395931AC-E6C9-4075-953E-5F8CE4236F54Q46675935-266BC94A-AEA2-4AC2-886E-275F3A2B20B8Q46784965-00154F39-3B96-441D-B018-C2261FDCE637Q46823814-8DBE97BB-0C31-4D92-A286-C5E5B59FF088Q46897650-C45F1B09-22D9-4412-9F15-DED3E62A7035Q47442417-D646A2B5-0CBC-4D83-B7DF-7E16A4B90364Q47628823-5D540FC9-3AD3-479D-90A4-820A09FEB90DQ50773348-1C8DD1A3-0F6E-41C9-9145-9980C8B114D2Q51356301-79418E66-755D-416A-9D73-8DC27E48D91CQ51489539-F11378CE-459C-4D1E-8244-80ED5EF2DEAE
P2860
Serum insulin and leptin levels in valproate-associated obesity.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Serum insulin and leptin levels in valproate-associated obesity.
@en
Serum insulin and leptin levels in valproate-associated obesity.
@nl
type
label
Serum insulin and leptin levels in valproate-associated obesity.
@en
Serum insulin and leptin levels in valproate-associated obesity.
@nl
prefLabel
Serum insulin and leptin levels in valproate-associated obesity.
@en
Serum insulin and leptin levels in valproate-associated obesity.
@nl
P2093
P2860
P1433
P1476
Serum insulin and leptin levels in valproate-associated obesity.
@en
P2093
Arto Pakarinen
Jouko I T Isojärvi
Jukka Turkka
Mervi Kotila
Virpi Pylvänen
P2860
P304
P356
10.1046/J.1528-1157.2002.31501.X
P50
P577
2002-05-01T00:00:00Z